← Eichor
Study identifier: NCT07738107 Synced from ClinicalTrials.gov · July 31, 2026
● Not Yet Recruiting

ATR 1072 in Participants With PRKAG2 Syndrome

Condition: Cardiac Glycogenosis · Cardiomyopathy · Hypertrophic  ·  Sponsor: Atrium Therapeutics

PhasePhase 1/Phase 2
Planned participants37
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.

This description comes directly from the study's public registry record.

Talk to the study team

Patient Recruitment Coordinator  ·  283-227-6543  ·  clinicaltrials@atrium-tx.com

Always discuss trial participation with your own doctor first.

Locations (0)

Locations not yet listed on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07738107